CT-histogram approach to predict lymph node metastasis in patients with c-stage IA lung cancer
This study aimed to clarify whether CT-histogram analysis of tumors can be used to classify patients with clinical stage 0-IA non-small cell lung cancer (c0-IA NSCLC) according to pathological lymph node (pN) status.MethodsPredictive factors associated with pN metastasis (pNM) were identified from the derivation dataset including 629 patients with c0-IA NSCLC who underwent complete resection with lymph node dissection (surgeries between 2008 and 2013). The validation dataset including 238 patients (surgeries between 2014 and 2015) were subsequently re-evaluated. Clinico-surgical factors, including CT-histogram parameters of tumors (2.5th, 25th, 50th, 75th, and 97.5th percentile CT values, skewness, and kurtosis) were assessed.ResultsSeventy-three patients in the derivation cohort (12%) and 35 patients in the validation cohort (15%) had positive nodes. pN status significantly affected survival in the entire population (5-year overall survival of 93.1% versus 71.1% and 5-year disease-free survival of 85.9% versus 43.1% for negative versus positive; both p
ConclusionsFurther studies are warranted to establish appropriate eligible criteria and management strategies for Chinese populations.
ConclusionDespite its limitations, this study is the first which suggests that CTHA could play a role in stratifying prognosis and treatment response in patients with NSCLC treated with Nivolumab.
Conclusion :18F-FDG PET/CT metabolic parameters combined with clinicopathological data demonstrated moderate diagnostic efficacy in predicting EGFR mutation status and were associated with prognosis in mutant and wild-type EGFR non-small-cell lung cancer, thus providing a reference for individualized targeted molecular therapy.
This study was performed in order to define the prevalence of mediastinal LN metastases discovered on combined endosonography by endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) fine needle aspiration in patients with a radiologically normal mediastinum. This study consists of a retrospective, single-institution, tertiary care referral center review of a prospectively maintained database.
AbstractPurposeInflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS).MethodsRetrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment F...
We report on a case of pseudoprogression, which was presented as intestinal perforation after pembrolizumab immunotherapy for NSCLC. A-54-year-old man with stage IV NSCLC received pembrolizumab therapy. The patient was admitted to our hospital because of acute abdominal pain and the computed tomography scan revealed diffuse wall thickening of the small bowel with free intraperitoneal air. Intestinal perforation was suspected and surgical resection was performed. Histological evaluation of the resected specimen showed infiltrated lymphocytes positive for CD3, CD8 with necrotic tumor cells, suggestive of an immune reaction. ...
Conclusion The entire tumor burden evaluated by 18F-FDG PET/CT can be predictive of response to immunotherapy in patients with metastatic lung cancer. A large prospective multicenter trial is warranted to definitively assess the usefulness of 18F-FDG PET/CT as a predictive biomarker of response to immunotherapy.
Conclusion A predictive model using PET/CT images might be used to detect EGFR mutation status in non-small cell lung cancer patients.
CONCLUSION: A 10-20 Gy radiation dose to anatomic or perfused lung results in decline in FEV1. A fractional anatomic volume of>5% receiving>50 Gy influences development of RALI. ADVANCES IN KNOWLEDGE: Extent of low-dose radiation to normal lung influences functional respiratory decline. PMID: 31287737 [PubMed - as supplied by publisher]
Lung cancer continues to be the leading cause of cancer-related death in the U.S.  Approximately 75% of patients with locally advanced non-small cell lung cancer (LANSCLC, stage IIIa/b 7th edition AJCC) receiving definitive multimodal treatment that includes chemoradiotherapy with or without surgery will recur. Given the high rates of recurrence, most patients are followed with intensive surveillance strategies that typically involve CT imaging at set intervals post-treatment with the hope that early detection of recurrence or a new primary cancer may improve outcome.